Compare · CHFS vs TMDX
CHFS vs TMDX
Side-by-side comparison of CHF Solutions, Inc. (CHFS) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CHFS and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX carries a market cap of $2.52B.
- TMDX has hit the wire 12 times in the past 4 weeks while CHFS has been quiet.
- TMDX has more recent analyst coverage (18 ratings vs 0 for CHFS).
- Company
- CHF Solutions, Inc.
- TransMedics Group Inc.
- Price
- -
- $72.87-1.11%
- Market cap
- -
- $2.52B
- 1M return
- -
- +13.59%
- 1Y return
- -
- -48.99%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- 2019
- News (4w)
- 0
- 12
- Recent ratings
- 0
- 18
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest CHFS
- Nuwellis to Advance Treatment of Critically-Ill Children and Babies Under $1.7 Million NIH Grant
- Nuwellis, Inc. To Announce Second Quarter 2021 Financial Results on August 10, 2021
- American Medical Association Issues New CPT Code for Nuwellis' Aquadex Ultrafiltration
- Nuwellis Announces New Appointments to Leadership Team
- Nationwide Access to Ultrafiltration Therapy Possible with Nuwellis and Premier, Inc. Collaboration
- ACC 2021 Presentation Adds to Body of Evidence Supporting Nuwellis Ultrafiltration to Treat Patients with Heart Failure
- Nuwellis, Inc. Announces 18 Percent Increase in Revenue for First Quarter 2021 Over Previous Year and Provides Company Update
- Nuwellis, Inc. To Announce First Quarter 2021 Financial Results on May 11, 2021
- CHF Solutions Expands Commercial Focus, Changes Name to Nuwellis
- CHF Solutions, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
Latest TMDX
- SEC Form SD filed by TransMedics Group Inc.
- Director Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Gunderson Thomas J. was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Raines Merilee was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Weill David was granted 2,922 shares, increasing direct ownership by 24% to 15,056 units (SEC Form 4)
- Director Lovell Stephanie was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Tobin James R was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Kania Edwin was granted 2,922 shares, increasing direct ownership by 1% to 263,732 units (SEC Form 4)
- Officer Forsyth Matthew S. was granted 15,409 shares (SEC Form 4)
- SEC Form 8-K filed by TransMedics Group Inc.